

**Facilitating Antibacterial Drug Development for Patients With Unmet Need and
Developing Antibacterial Drugs That Target a Single Species—July 18 and 19, 2016**

Speakers and Panelists

Paul Ambrose, Pharm.D.

President
Institute for Clinical Pharmacodynamics, Inc.

Luciana Borio, M.D.

Acting Chief Scientist
FDA

Helen Boucher, M.D.

Director, Infectious Diseases Fellowship Program and Associate Professor of Medicine
Tufts University School of Medicine

Samuel Bozzette, M.D., Ph.D.

Vice President, Medical Affairs – Americas/East Asia and Global Health Economics and
Outcomes, BioMérieux, Inc.
Adjunct Professor of Medicine and of International Relations, University of California, San
Diego
Adjunct Professor of Health Policy and Management, University of North Carolina

Marco Cavaleri, Ph.D.

Head of Anti-Infectives and Vaccines
European Medicine Agency

Edward Cox, M.D., M.P.H.

Director, Office of Antimicrobial Products (OAP)
CDER, FDA

Aaron Dane, M.Sc.

Director, DaneStat Consulting

Dennis Dixon, Ph.D.

Chief, Bacteriology and Mycology Branch
NIAID, NIH

Michael Dudley, Pharm.D.

Senior Vice President and Head, R&D
Co-Leader, Infectious Diseases Global Innovation Group
The Medicines Company

Ian Friedland, M.D.

Chief Medical Officer
Achaogen, Inc.

John Jenkins, M.D.

Director, Office of New Drugs
CDER, FDA

Nick Kartsonis, M.D.

Associate Vice President, Clinical Research;
Section Head, Antibacterials, Antifungals, HIV & CMV
Merck & Co., Inc.

Peter Kim, M.D., M.S.

Medical Officer, Division of Anti-Infective Products
OAP, CDER, FDA

Joe Larsen, Ph.D.

Deputy Director (Acting)
Biomedical Advanced Research Development Authority (BARDA)

Thomas Louis, Ph.D.

Professor, Department of Biostatistics
Johns Hopkins University Bloomberg School of Public Health

Lynn Marks, M.D.

Senior Vice President for Projects, Clinical Platforms, and Sciences
GlaxoSmithKline, plc

Sumathi Nambiar, M.D., M.P.H.

Director, Division of Anti-Infective Products
OAP, CDER, FDA

John Powers, M.D.

Senior Medical Scientist
NIAID, NIH

John Rex, M.D.

Senior VP and Chief Strategy Officer, Infection Business Unit
AstraZeneca, plc

Dan Rubin, Ph.D.

Statistical Reviewer, Office of Biostatistics
CDER, FDA

John Tomayko, M.D.

Chief Medical Officer
Spero Therapeutics

Kert Viele, Ph.D.

Director & Senior Statistical Scientist
Berry Consultants

Disclosures

Dr. Ambrose is an employee of the Institute for Clinical Pharmacodynamics, Inc., a company that provides pharmacometric services to the pharmaceutical industry.

Dr. Boucher has served as a consultant to Merck&Co., Inc. and served on Data Monitoring Committees for Actelion Ltd. and Cardeas Pharma.

Dr Bozzette is an employee of BioMérieux, Inc.

Mr. Dane provides statistical consultation to the pharmaceutical industry.

Dr. Dudley is an employee of The Medicines Company.

Dr. Friedland is an employee of Achaogen, Inc.

Dr. Kartsonis is an employee of Merck&Co., Inc.

Dr. Rex is an employee of AstraZeneca, plc., and provides consultative support and advice to various pharmaceutical companies.

Dr. Tomayko is an employee of Spero Therapeutics.

Dr. Viele provides statistical consultation to the pharmaceutical industry.